Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • NUFYMCO BLA has been approved by the USFDA
    27 December 2025

    Zydus Life sciences strategic partnership with Bioeq for NUFYMCO

    Bioeq AG, a Swiss biopharmaceutical company, and Zydus Lifesciences Limited , an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO® has been approved by U.S.

  • 26 December 2025
    New Global Study Questions Tramadol Use for Long-Term Pain Relief
    A new large systematic review published this week has raised important questions about the safety and effectiveness of tramadol, a widely prescribed opioid for chronic pain relief. The study, published online ahead of print in BMJ Evidence-Based Medicine, finds that while tramadol does reduce pain compared with placebo, the benefit is small and may not be clinically meaningful for many patients.
  • 26 December 2025
    Sanofi’s moves into adult Vaccines: Buying Dynavax in 2.2 billion USD
    In a strategic development that’s set to reshape its vaccine business, Sanofi has announced an agreement to acquire Dynavax Technologies Corporation, a U.S.-based vaccines company known for its marketed adult hepatitis B vaccine and an early-stage shingles vaccine candidate.
  • 26 December 2025
    New Hope for Thalassemia Patients as FDA Greenlights Agios’ Aqvesme – But Cautions Remain
    A major breakthrough for adults living with rare inherited blood disorders, the U.S. Food and Drug Administration (FDA) has officially approved Agios Pharmaceuticals’ oral drug AQVESME™ (mitapivat) for the treatment of anemia in both alpha- and beta-thalassemia, regardless of whether patients require regular blood transfusions or not.
  • 26 December 2025
    Biofabri–Bharat Biotech pact brings fresh hope in global fight against Tuberculosis
    Biofabri and Bharat Biotech International Limited have signed a technology transfer agreement aimed at improving worldwide access to the promising TB vaccine candidate, MTBVAC.
  • 24 December 2025
    New WHO Report Shows Big Gaps in Global Genomics Research
    The World Health Organization (WHO) has come out with a new global analysis that shows there are major equity gaps in human genomics research, especially between rich and poorer countries.
  • 23 December 2025
    Neurocrine dyskinetic cerebral palsy medicine fails in clinical trial
    The study – the largest double-blind placebo-controlled clinical trial ever completed in DCP – evaluated the efficacy of 14 weeks of treatment with valbenazine compared with placebo in pediatric and adult participants who have dyskinesia due to cerebral palsy with choreiform movements. Adverse events were generally consistent with the established safety profile for valbenazine.
  • 23 December 2025
    Novo Nordisk Receives USFDA approval for Wegovy pill in the US
    Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.
  • 19 December 2025
    Pfizer & Cipla Announce Exclusive Marketing and Distribution Partnership for Select Brands in India
    Pfizer India and Cipla Limited announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India.
  • 18 December 2025
    PLI Scheme drives manufacturing of 36 Medical Devices in India
    Total 36 different medical devices are manufactured under Production Linked Incentive (PLI) Scheme for promoting domestic manufacturing of medical devices in India. These medical devices belong to different portfolios such as Imaging & Diagnostics, Critical Care & Emergency, Interventional CardioVascular, Renal Care Devices, Orthopaedic Implants, Oncology and specialist divisions.
Subscribe to Pharma News